Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
WALTHAM, Mass. - Thermo Fisher Scientific Inc (BVMF:TMOS34). (NYSE: NYSE:TMO), with a market capitalization of $203 billion, has announced an increase in its quarterly cash dividend, demonstrating confidence in its financial performance. The board of directors approved a 10% hike, raising the dividend to $0.43 per common share, which will be payable on April 15, 2025, to shareholders on record as of March 14, 2025. According to InvestingPro, the company has maintained dividend payments for 13 consecutive years, with a current yield of 0.3%.
This decision marks an uptick from the previous dividend of $0.39 per share. Thermo Fisher, with annual revenues of $42.9 billion, positions itself as a global leader in serving the scientific community. The company’s extensive portfolio includes a variety of brands such as Thermo Scientific, Applied Biosystems, and Fisher Scientific, catering to diverse needs in life sciences research, laboratory productivity, diagnostics, and the development of therapies. InvestingPro analysis reveals the company maintains a GOOD financial health score, with particularly strong profitability metrics.
The dividend increase reflects Thermo Fisher’s commitment to providing value to its shareholders and its ability to maintain a stable financial outlook. As a provider of innovative technologies and services, Thermo Fisher continues to support critical sectors that aim to enhance global health, cleanliness, and safety.
The information regarding the dividend declaration is based on a press release statement from Thermo Fisher Scientific Inc.
In other recent news, Thermo Fisher Scientific reported strong fourth-quarter results for 2024, surpassing analyst expectations. The company’s adjusted earnings per share (EPS) reached $6.10, exceeding the forecast of $5.95, while revenue hit $11.4 billion, surpassing the expected $11.29 billion. Analysts from Bernstein, RBC Capital Markets, and Stifel have all maintained positive ratings on the company, with Bernstein and RBC raising their price targets to $690 and $693, respectively. Stifel continues to hold a Buy rating with a price target of $665, citing Thermo Fisher’s robust performance and promising guidance for 2025. The company’s 2025 outlook includes a projected revenue range of $43.5 to $44.0 billion and an EPS range of $23.10 to $23.50. Thermo Fisher anticipates organic growth of 3-4% and an operating margin expansion of 90 basis points. This outlook is supported by strategic initiatives, including product innovations and partnerships, which analysts believe position the company favorably for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.